Shares of Kura Oncology Inc (NASDAQ:KURA) have been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $26.20.
Several brokerages have recently weighed in on KURA. JMP Securities reissued a “market outperform” rating and set a $22.00 price objective on shares of Kura Oncology in a report on Thursday, September 5th. Zacks Investment Research lowered Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, November 12th. Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Friday. ValuEngine raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Finally, Wedbush reissued a “positive” rating on shares of Kura Oncology in a report on Wednesday, September 4th.
A number of hedge funds have recently made changes to their positions in KURA. Brown Advisory Inc. acquired a new stake in Kura Oncology in the 2nd quarter valued at $11,799,000. State Street Corp boosted its stake in Kura Oncology by 52.0% in the 3rd quarter. State Street Corp now owns 1,226,528 shares of the company’s stock valued at $18,606,000 after buying an additional 419,582 shares in the last quarter. Vanguard Group Inc. boosted its stake in Kura Oncology by 23.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock valued at $39,628,000 after buying an additional 376,172 shares in the last quarter. Marshall Wace LLP boosted its stake in Kura Oncology by 1,449.5% in the 2nd quarter. Marshall Wace LLP now owns 347,698 shares of the company’s stock valued at $6,846,000 after buying an additional 325,258 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Kura Oncology in the 2nd quarter valued at $5,940,000. 88.72% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:KURA traded up $0.09 during trading on Thursday, hitting $15.79. 374,140 shares of the stock were exchanged, compared to its average volume of 262,943. Kura Oncology has a 1-year low of $12.30 and a 1-year high of $21.42. The company has a market capitalization of $713.18 million, a price-to-earnings ratio of -9.18 and a beta of 2.56. The company’s fifty day simple moving average is $15.25 and its 200-day simple moving average is $16.81. The company has a debt-to-equity ratio of 0.03, a quick ratio of 19.29 and a current ratio of 19.29.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. On average, research analysts forecast that Kura Oncology will post -1.53 earnings per share for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: Hang Seng Index (HSI)
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.